In a $46 million deal expected to go ahead by the end of the year, Nabi Biopharmaceuticals has sold its staph infection vaccine PentaStaph, to GlaxoSmithKline PLC. PentaStaph is being taken into third phase trials of patients with renal disease patients and is a modified version of StaphVax, a drug licensed from the National Institutes of Health by Nabi. The deal leaves the company with NicVax, a smoking-cessation treatment that blocks nicotine from reaching the brain, as the company"s only flagship product.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지